Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), which has seen its stock decline over 50% in the past year according to InvestingPro data, recently reported that Patrick O'Brien, the company's Chief Operating Officer and General Counsel, sold shares totaling $736,058. The transactions occurred on January 6 and January 7, 2025, and involved the sale of 37,184 shares at prices ranging from $19.69 to $20.10.
The sales were made under a pre-established 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for buying or selling stocks to avoid potential conflicts of interest. These transactions were part of a partial disposition of restricted stock units (RSUs) to satisfy tax withholding obligations.
Following these sales, O'Brien retains ownership of 527,201 shares in the company, which includes shares underlying RSUs subject to vesting conditions.
In other recent news, Arrowhead Pharmaceuticals has seen significant strides in its operations and financial status. Analysts from B.Riley and H.C. Wainwright have maintained their Buy rating on the company's stock, highlighting Arrowhead's dominance in the siRNA therapeutics market and the potential of its pipeline. Despite a net loss reported for fiscal 2024, the company's robust cash and investment balance, bolstered by a transformative partnership with Sarepta Therapeutics (NASDAQ:SRPT), is expected to sustain operations until 2028.
The collaboration with Sarepta involves substantial upfront payments and potential additional payouts that could significantly support Arrowhead's financial and developmental goals. This partnership is viewed as crucial for the anticipated commercial launch of Arrowhead's first RNA interference therapeutic in 2026, pending approval.
Arrowhead's lead program, plozasiran, has seen progress with a New Drug Application submitted for Familial Chylomicronemia Syndrome. The company is also engaged in several Phase III trials and has introduced two new obesity programs, highlighting its ongoing commitment to innovation in RNAi therapeutics.
However, Bernstein SocGen Group, Piper Sandler, and Citi have adjusted their price targets for Arrowhead, while maintaining their respective ratings on the stock. These adjustments follow Arrowhead's recent updates and the announcement of the significant strategic partnership with Sarepta Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.